Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Lineage Cell Therapeutics Issues Letter to Stockholders
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.